Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.09 USD
+0.01 (0.93%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.08 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ONCY 1.09 +0.01(0.93%)
Will ONCY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCY
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) to Report Q1 Earnings: What to Expect?
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
New Strong Buy Stocks for January 18th
Other News for ONCY
Oncolytics Biotech Showcases Cancer Advances at ASCO
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech to Present at ASCO Meeting
Oncolytics Biotech Sets Virtual Annual Meeting
Oncolytics Biotech Targets FDA Approval for Cancer Drug